A "New Door" in Pancreatic Cancer Treatment: The Impact of an Oral Medication that Doubled Survival Time

A "New Door" in Pancreatic Cancer Treatment: The Impact of an Oral Medication that Doubled Survival Time

A "New Door" in Pancreatic Cancer Treatment: The Hope and Challenges Posed by an Oral Medication That Doubled Survival Time

The diagnosis of pancreatic cancer carries a weight unlike many other cancers. Often, it is already advanced by the time it is discovered, leaving limited treatment options and forcing patients and their families into a battle against "time." Despite advancements in chemotherapy, there have been few dramatic breakthroughs. For doctors, pancreatic cancer has been emblematic of cancers where "it is difficult to speak of hope."

In the treatment of pancreatic cancer, oncologists around the world stood up in surprise. This was due to the announcement of the phase 3 trial results of an oral drug called Daraxonrasib at the annual meeting of the American Society of Clinical Oncology in Chicago. The trial targeted patients with metastatic pancreatic ductal adenocarcinoma whose disease had progressed after initial treatment. In a trial involving about 500 participants, the median overall survival for patients taking Daraxonrasib was 13.2 months, nearly double the 6.6 to 6.7 months for the standard chemotherapy group.

Looking at the numbers alone, some might perceive this as just "a few months' difference." However, in the context of pancreatic cancer, especially metastatic pancreatic cancer, this difference is significant. For patients with advanced disease, six months is not merely a statistic. It is time to celebrate a grandchild's birthday, to go on a family trip, and to regain a sense of normalcy while continuing treatment. This is why healthcare providers regard these results as "groundbreaking" and "historic."

The drug targets a cancer-related protein known as RAS. Among these, KRAS has been recognized as a critical genetic mutation involved in many pancreatic cancers. However, for a long time, KRAS was considered "undruggable," meaning it was a difficult target for medication. This was because its structure made it challenging for drugs to bind, and methods to halt the cancer cell growth signals were hard to find.

Nevertheless, researchers have persisted through basic research, structural biology, drug discovery chemistry, and clinical trials. Daraxonrasib was developed as a new type of inhibitor targeting the activated state of RAS. Unlike traditional chemotherapy, which tends to broadly affect both cancerous and normal cells, treatments targeting RAS aim to approach the cancer's driving factors directly.

Of course, this is not a story of a "cure for pancreatic cancer." It is important not to misunderstand this. Daraxonrasib has shown promise in trials targeting patients with previously treated metastatic pancreatic cancer, but issues of drug resistance remain. Cancer cells often find alternative escape routes. Even if tumors are suppressed while the treatment is effective, they may begin to grow again over time. Physicians are now looking towards combining it with other drugs or using it at earlier stages of treatment.

Nonetheless, the results have a clear significance. In pancreatic cancer treatment, it demonstrated that molecular targeted therapies can offer substantial survival benefits, as shown in a rigorous phase 3 trial. The long-held belief that "pancreatic cancer is difficult" and "KRAS cannot be targeted" has been at least partially overturned. Beyond improving treatment outcomes, it also provides researchers and pharmaceutical companies with the rationale to "invest further in this area."

There are also notable points regarding side effects. According to reports, Daraxonrasib frequently caused rash, stomatitis, nausea, and diarrhea. Rashes were reported to occur at a high frequency, with some severe cases. However, the rate of treatment discontinuation due to side effects was reportedly lower than that of the chemotherapy group. This is important for patients because cancer treatment is not only about "how long one can live" but also "how one can spend that time."

An article in the Washington Post mentioned a trial participant who, despite being hospitalized due to nausea, found it easier to maintain strength with dose adjustments compared to chemotherapy. Reuters also highlighted cases where patients returned to activities like travel and golf due to the treatment. While these individual experiences are not the trial results themselves, they are indispensable in considering the value of the drug. Behind the cold numbers of median survival time lies the warm reality of quality of life.

The reaction on social media was significant. On X, the topic of "a new pancreatic cancer drug doubling survival time" trended, drawing attention from healthcare professionals, cancer survivors, and patients' families in the Japanese-speaking community. The prominent reactions were those of surprise and hope, with posts expressing sentiments like "I understand why there was a standing ovation at ASCO," "This number is really big for pancreatic cancer," and "Considering the previous despair, it brings tears."

 

On Reddit's pancreatic cancer community, more emotional reactions were observed. One post described a medical oncologist specializing in pancreatic cancer shedding tears while watching the announcement at home. This reflects the long-standing perception of pancreatic cancer research as a "challenging field with few results." Another post noted that people standing up when the survival curve was shown at the conference is "not something that usually happens during a conference presentation."

On LinkedIn, there were many reactions from doctors, researchers, and pharmaceutical industry professionals. Words like "game changer," "practice-changing," and "potential new standard treatment" were common. However, the expert reactions were not just unreserved praise. Points to be considered calmly include the fact that the drug is not yet approved, the conditions of the target patients, the types of RAS mutations, the management of side effects in real clinical settings, drug pricing and access, and post-resistance treatment strategies.

The reactions from patients' families are even more pressing. On social media, practical questions such as "Will my family member be eligible?" "Can we access it from outside the US?" and "How can we use the expanded access program?" were seen. In May, the US FDA approved an expanded access treatment protocol for Daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma. While this is not approval itself, it is a system that expands the possibility for patients who meet certain conditions to access investigational drugs for serious diseases.

However, caution is needed here as well. Expanded access is not a system where anyone can immediately receive the drug. Physicians must apply to the pharmaceutical company and go through necessary reviews and procedures. Circumstances vary by country and medical institution, and Japanese patients may not be able to use the same system as it is. If it spreads on social media as if it were a "readily available drug," it could raise excessive expectations among patients and families.

What is important in this news is to hold both hope and caution simultaneously. In pancreatic cancer treatment, the results of Daraxonrasib are indeed significant. The median survival time nearly doubled, progression-free survival improved, and reports indicate tumor shrinkage and improved quality of life. Considering the history of pancreatic cancer treatment, it is natural to want to call this the "entrance to a new era."

On the other hand, it does not work for all patients. The side effects are not light either. There are many issues to be confirmed in the future, such as final approval, insurance coverage, timing of use in various countries, safety in real clinical settings, long-term resistance, and optimization of combination therapies. When patients consider treatment, they need to consult with their primary doctor and confirm each aspect, such as their cancer's genetic mutations, treatment history, physical strength, organ function, and the possibility of participating in clinical trials.

Still, the reason why this announcement moved people's hearts is clear. For pancreatic cancer, a disease long seen as having "no visible breakthrough," a grounded hope was shown for the first time. Hope is not mere optimism. It is the culmination of patients who participated in trials, past failed research, researchers who supported basic science, and healthcare providers who continued treatment, finally manifesting as a single number.

Daraxonrasib is not the goal of pancreatic cancer treatment. It is closer to the starting point. Based on this, there is a need for combinations that work longer, treatments at earlier stages, and system designs that reach more patients. The standing ovation at the ASCO venue was applause for a single drug and applause for the long-held wish that "pancreatic cancer might be changeable."

In pancreatic cancer treatment so far, both doctors and patients have devoted themselves to "extending time even a little." This time, the possibility of significantly expanding that time has been shown. Even if it is not yet a complete answer, this is a significant step forward. In the heavy silence that has surrounded the word pancreatic cancer, the next words are finally being born.

Those words are "It is not over yet."


Source URL

Related Articles